Silexion Therapeutics (SLXN) AI Stock Analysis

• Market Cap: $6.57M
• Dividend Yield: N/A
• Average Volume (3M): 49.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 91.47%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.88
• Shares Outstanding: 3,126,642
• 10 Day Avg. Volume: 57,606
• 30 Day Avg. Volume: 49,293
• PEG Ratio: -0.28
• Price to Book (P/B): -47.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.34
• Enterprise Value/Market Cap: -0.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 484.71
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $9.00
• Price Target Upside: 307.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -3.99
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-9.50% Downside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and accelerating cash burn) and a bearish technical setup (below key moving averages with negative MACD). Positive corporate developments around regulatory progress and trial preparations provide an offset, but valuation metrics are not informative/supportive due to negative earnings and no stated dividend.

Positive Factors

Preclinical potency across KRAS mutations

Demonstrated high in vitro inhibition across diverse KRAS mutations suggests a broad and differentiated biological profile versus mutation-restricted therapies. This increases the likelihood of clinically meaningful signals, supports a larger addressable patient pool, and strengthens potential for partnerships and long-term commercial relevance.

Regulatory clarity from BfArM and filings underway

Positive scientific advice and multi-jurisdiction filings materially reduce regulatory design risk and accelerate a path to clinic. Clear guidance on trial design and CMC supports efficient study setup, enhances credibility with partners/investors, and improves the odds of timely, durable clinical development execution.

Toxicology clearance supporting clinical start

Two-species toxicology with no systemic organ toxicity is a durable safety milestone that underpins regulatory submissions and first-in-human plans. Coupled with a selected CRO and manufacturing readiness, it materially lowers preclinical safety risk and supports smoother, faster transition into clinical development.

Negative Factors

Pre-revenue with sustained losses

As a pre-commercial biotech, the company lacks operating revenue and relies entirely on external capital while burning significant cash. Persistent net losses limit financial flexibility over the medium term and make long-term strategy contingent on successful clinical data or partnership funding to avoid dilutive financings.

Rising and deteriorating cash burn trend

A clear trend of increasing negative operating and free cash flow shortens runway absent new capital or revenue. This elevates execution risk for lengthy Phase 2/3 programs and increases the probability of future equity or debt raises, which can dilute shareholders and complicate long-term planning.

Limited balance sheet scale and prior equity weakness

Although equity is now positive, the company has a small asset base, modest absolute cash, and a history of negative equity. Combined with a very small team, this constrains the company's ability to internally support complex global Phase 2/3 operations and increases reliance on external partners and capital.

Silexion Therapeutics Business Overview & Revenue Model

Company Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

How the Company Makes Money

Silexion Therapeutics generates revenue primarily through the sale of its proprietary pharmaceutical products, which are developed in-house and marketed globally. The company also engages in licensing agreements with other pharmaceutical firms, allowing them to commercialize Silexion's patented technologies in exchange for royalties and milestone payments. Additionally, strategic partnerships with research institutions and healthcare providers contribute to its earnings by facilitating collaborative development projects and expanding its market reach.

Silexion Therapeutics Financial Statement Overview

Summary

Silexion Therapeutics faces significant financial challenges, including zero revenue and negative equity, posing major risks. While there is an improvement in net income and operating cash flow, the lack of revenue generation and high leverage create concerns for future sustainability.

Income Statement

Silexion Therapeutics has consistently reported zero revenue over the past three years, which is concerning for a company in the biotechnology industry. The net income improved significantly in 2024, turning positive after previous losses, indicating potential improvements in cost management or business operations. However, the lack of revenue generation remains a critical issue.

Balance Sheet

The balance sheet shows significant challenges, with stockholders' equity being negative in recent years and total liabilities exceeding total assets. The company's debt-to-equity ratio cannot be calculated due to negative equity, and this financial structure indicates high leverage and potential solvency risks. The absence of cash and cash equivalents in 2024 further adds to liquidity concerns.

Cash Flow

The cash flow position has seen some improvement, with operating cash flow increasing significantly towards a less negative figure in 2024. However, free cash flow remains negative, indicating ongoing challenges in generating cash from operations even though there is a positive shift in financing cash flow. The negative free cash flow to net income ratio suggests that the company is not yet in a stable cash generation position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-7.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-7.48M	-16.48M	-4.64M	-3.80M	-755.00K	-195.86K
Net Income	-7.53M	-16.44M	-4.94M	-3.21M	-755.22K	-195.86K
Balance Sheet
Total Assets	11.61M	2.86M	5.26M	9.33M	115.41M	129.40K
Cash, Cash Equivalents and Short-Term Investments	9.24M	1.19M	4.59M	8.26M	38.94K	51.70K
Total Debt	485.00K	4.49M	171.00K	271.00K	0.00	0.00
Total Liabilities	4.64M	6.85M	17.31M	16.41M	508.92K	299.39K
Stockholders Equity	6.98M	-3.99M	-15.48M	-10.66M	114.91M	-169.99K
Cash Flow
Free Cash Flow	-10.74M	-8.42M	-4.54M	-3.38M	-1.41M	-75.00K
Operating Cash Flow	-10.73M	-8.40M	-4.53M	-3.33M	-1.41M	-75.00K
Investing Cash Flow	-7.00K	-22.00K	573.00K	-524.00K	0.00	0.00
Financing Cash Flow	18.05M	5.10M	522.00K	2.75M	116.40M	126.70K

Silexion Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Negative. The current price of 2.21 is below the 20-day moving average (MA) of 2.36, below the 50-day MA of 2.65, and below the 200-day MA of 8.31, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 40.35 is Neutral, neither overbought nor oversold. The STOCH value of 57.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLXN.

Silexion Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	52 Neutral	$14.28M	0.22	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLTO	51 Neutral	$33.54M	-1.68	-114.81%	―	―	37.42%
LYRA	45 Neutral	$6.41M	-0.16	-404.48%	―	-59.21%	68.97%
SLXN	44 Neutral	$6.57M	-0.08	-771.23%	―	―	91.47%
RNAZ	44 Neutral	$6.85M	-0.03	-1763.01%	―	―	96.75%
MBIO	42 Neutral	$8.25M	-0.90	-418.83%	―	―	98.58%

Silexion Therapeutics Corporate Events

Silexion outlines 2026 plans after transformational 2025 progress

On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders detailing what it called a transformational 2025, highlighted by strong preclinical data for its lead RNAi asset SIL204, which showed over 90% inhibition of KRAS-mutated cancer cell growth across multiple mutations and tumor types, including pancreatic, colorectal, lung and other solid tumors. During 2025 the company also completed two-species toxicology studies with no systemic organ toxicity observed, received positive guidance from Germany’s BfArM on a planned Phase 2/3 trial design in locally advanced pancreatic cancer, secured manufacturing and clinical development partners, raised more than $18 million in financing and regained full Nasdaq compliance, steps that collectively move SIL204 closer to first-in-human testing and strengthen the firm’s positioning in the emerging pan-KRAS therapy space. Looking ahead, Silexion has completed regulatory submissions in Israel for a Phase 2/3 trial in locally advanced pancreatic cancer and plans additional filings in Germany, other EU countries and the U.S. in 2026, with a trial design that includes a safety run-in in combination with standard chemotherapy followed by a randomized expansion, a program it believes could generate pivotal human data to underpin future partnerships and funding while addressing a major unmet need in KRAS-driven cancers.

The most recent analyst rating on (SLXN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Therapeutics Submits Phase 2/3 Trial Application

On December 16, 2025, Silexion Therapeutics announced the submission of a Phase 2/3 clinical trial application in Israel for their siRNA therapy, SIL204, targeting locally advanced pancreatic cancer. This regulatory milestone follows successful preclinical studies and positive feedback from German authorities, positioning Silexion to initiate trials in Q2 2026, with further filings planned for Germany and the EU in Q1 2026 and potential U.S. expansion thereafter.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Therapeutics Gains Positive Feedback for SIL204 Trial

On December 2, 2025, Silexion Therapeutics announced it received positive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its Phase 2/3 clinical trial for SIL204, a treatment for pancreatic cancer. This feedback is a significant milestone, providing regulatory clarity and supporting the company’s trajectory towards initiating the trial in the first half of 2026, pending regulatory approvals in Israel and Germany. The company is actively preparing for the trial launch, including manufacturing readiness and clinical site preparations.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Completes Toxicology Studies for SIL204 Therapy

On November 25, 2025, Silexion Therapeutics announced the successful completion of toxicology studies for SIL204, a next-generation RNA silencing therapy targeting mutated KRAS oncogenes, ahead of its planned Phase 2/3 clinical trial in locally advanced pancreatic cancer. The studies confirmed no systemic organ toxicity, allowing the company to proceed with regulatory submissions in Israel and Germany and stay on track to initiate the trial in Q2 2026. This advancement strengthens Silexion’s position in the biotechnology industry, offering a promising treatment modality for aggressive cancers and potentially improving survival rates for patients with pancreatic cancer.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.